Protagonist Therapeutics, Inc.
PTGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $434 | $60 | $27 | $27 |
| % Growth | 624.1% | 125.7% | -2.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $434 | $60 | $27 | $27 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $138 | $120 | $126 | $126 |
| G&A Expenses | $43 | $33 | $32 | $27 |
| SG&A Expenses | $43 | $33 | $32 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $182 | $154 | $158 | $153 |
| Operating Income | $253 | -$94 | -$131 | -$126 |
| % Margin | 58.2% | -156.1% | -494.2% | -460% |
| Other Income/Exp. Net | $27 | $15 | $4 | $0 |
| Pre-Tax Income | $279 | -$79 | -$127 | -$126 |
| Tax Expense | $4 | $0 | $0 | $0 |
| Net Income | $275 | -$79 | -$127 | -$126 |
| % Margin | 63.3% | -131.6% | -479.3% | -458.9% |
| EPS | 4.47 | -1.39 | -2.52 | -2.65 |
| % Growth | 421.6% | 44.8% | 4.9% | – |
| EPS Diluted | 4.23 | -1.39 | -2.52 | -2.65 |
| Weighted Avg Shares Out | 62 | 57 | 49 | 46 |
| Weighted Avg Shares Out Dil | 65 | 57 | 49 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26 | $15 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $3 | $3 | $3 |
| EBITDA | $254 | -$90 | -$128 | -$123 |
| % Margin | 58.4% | -150.6% | -481.6% | -449.9% |